Summary

Retinal Vein Occlusion Market – Scope of Report
TMR’s report on the global retinal vein occlusion market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global retinal vein occlusion market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global retinal vein occlusion market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the retinal vein occlusion market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global retinal vein occlusion market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global retinal vein occlusion market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global retinal vein occlusion market.

The report delves into the competitive landscape of the global retinal vein occlusion market. Key players operating in the global retinal vein occlusion market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global retinal vein occlusion market profiled in this report.

Key Questions Answered in Global retinal vein occlusion Market Report
• What is the sales/revenue generated by retinal vein occlusion across all regions during the forecast period?
• What are the opportunities in the global retinal vein occlusion market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Retinal Vein Occlusion Market – Research Objectives and Research Approach
The comprehensive report on the global retinal vein occlusion market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global retinal vein occlusion market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global retinal vein occlusion market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Retinal Vein Occlusion Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Retinal Vein Occlusion Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Regulatory Scenario
5.2. PESTLE Analysis
5.3. Healthcare Expenditure by Region/Country (Health spending Total, US dollars/capita, 2022)
5.4. Go-to-Market Strategies for Retinal Vein Occlusion Market
5.5. Value Chain Analysis
5.6. Treatment Algorithm
5.7. Key Industry Events
6. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Disease Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Disease Type, 2020-2034
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Market Attractiveness By Disease Type
7. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Treatment Type, 2020-2034
7.3.1. Pharmacological Treatment
7.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
7.3.1.2. Corticosteroid Drugs
7.3.2. Laser Treatment
7.3.2.1. Panretinal Photocoagulation
7.3.2.2. Focal Laser
7.3.3. Vitrectomy
7.4. Market Attractiveness By Treatment Type
8. Global Retinal Vein Occlusion Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals and Ambulatory Surgical Centers
8.3.2. Ophthalmology Clinics
8.3.3. Retail Pharmacies
8.3.4. Others
8.4. Market Attractiveness By End-user
9. Global Retinal Vein Occlusion Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Region
10. North America Retinal Vein Occlusion Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Disease Type, 2020-2034
10.2.1. Central Retinal Vein Occlusion
10.2.2. Branch Retinal Vein Occlusion
10.3. Market Value Forecast By Treatment Type, 2020-2034
10.3.1. Pharmacological Treatment
10.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
10.3.1.2. Corticosteroid Drugs
10.3.2. Laser Treatment
10.3.2.1. Panretinal Photocoagulation
10.3.2.2. Focal Laser
10.3.3. Vitrectomy
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals and Ambulatory Surgical Centers
10.4.2. Ophthalmology Clinics
10.4.3. Retail Pharmacies
10.4.4. Others
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Treatment Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Retinal Vein Occlusion Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Disease Type, 2020-2034
11.2.1. Central Retinal Vein Occlusion
11.2.2. Branch Retinal Vein Occlusion
11.3. Market Value Forecast By Treatment Type, 2020-2034
11.3.1. Pharmacological Treatment
11.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
11.3.1.2. Corticosteroid Drugs
11.3.2. Laser Treatment
11.3.2.1. Panretinal Photocoagulation
11.3.2.2. Focal Laser
11.3.3. Vitrectomy
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals and Ambulatory Surgical Centers
11.4.2. Ophthalmology Clinics
11.4.3. Retail Pharmacies
11.4.4. Others
11.5. Market Value Forecast By Country / Sub-region, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Treatment Type
11.6.3. By End-user
11.6.4. By Country / Sub-region
12. Asia Pacific Retinal Vein Occlusion Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Disease Type, 2020-2034
12.2.1. Central Retinal Vein Occlusion
12.2.2. Branch Retinal Vein Occlusion
12.3. Market Value Forecast By Treatment Type, 2020-2034
12.3.1. Pharmacological Treatment
12.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
12.3.1.2. Corticosteroid Drugs
12.3.2. Laser Treatment
12.3.2.1. Panretinal Photocoagulation
12.3.2.2. Focal Laser
12.3.3. Vitrectomy
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals and Ambulatory Surgical Centers
12.4.2. Ophthalmology Clinics
12.4.3. Retail Pharmacies
12.4.4. Others
12.5. Market Value Forecast By Country / Sub-region, 2020-2034
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Treatment Type
12.6.3. By End-user
12.6.4. By Country / Sub-region
13. Latin America Retinal Vein Occlusion Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Disease Type, 2020-2034
13.2.1. Central Retinal Vein Occlusion
13.2.2. Branch Retinal Vein Occlusion
13.3. Market Value Forecast By Treatment Type, 2020-2034
13.3.1. Pharmacological Treatment
13.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
13.3.1.2. Corticosteroid Drugs
13.3.2. Laser Treatment
13.3.2.1. Panretinal Photocoagulation
13.3.2.2. Focal Laser
13.3.3. Vitrectomy
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals and Ambulatory Surgical Centers
13.4.2. Ophthalmology Clinics
13.4.3. Retail Pharmacies
13.4.4. Others
13.5. Market Value Forecast By Country / Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Treatment Type
13.6.3. By End-user
13.6.4. By Country / Sub-region
14. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Disease Type, 2020-2034
14.2.1. Central Retinal Vein Occlusion
14.2.2. Branch Retinal Vein Occlusion
14.3. Market Value Forecast By Treatment Type, 2020-2034
14.3.1. Pharmacological Treatment
14.3.1.1. Anti-vascular endothelial growth factor (anti-VEGF) Drugs
14.3.1.2. Corticosteroid Drugs
14.3.2. Laser Treatment
14.3.2.1. Panretinal Photocoagulation
14.3.2.2. Focal Laser
14.3.3. Vitrectomy
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals and Ambulatory Surgical Centers
14.4.2. Ophthalmology Clinics
14.4.3. Retail Pharmacies
14.4.4. Others
14.5. Market Value Forecast By Country / Sub-region, 2020-2034
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Disease Type
14.6.2. By Treatment Type
14.6.3. By End-user
14.6.4. By Country / Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Alimera Sciences
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Abbivie
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. Annexin Pharmaceuticals AB
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. F. Hoffmann-La Roche AG
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Novartis AG
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. IRIDEX Corporation
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Lumenis
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Nidek Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Regeneron Pharmaceuticals, Inc.
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments